European Pharmaceutical Review

MAY 7, 2024

percent compound annual growth rate (CAGR) between 2024 to 2029. billion by 2029. by 2029 appeared first on European Pharmaceutical Review. A new report by MarketsandMarkets has predicted that the injectable drug delivery market will reach an 8.6 The market is anticipated to value $1139.4 Eli Lilly and Company and Sandoz.

Vaccines 94

Vaccines Compounding Immunization FDA 94

STAT

SEPTEMBER 19, 2024

Hims & Hers Health plans to sell compounded versions of Novo Nordisk’s popular weight loss drug Wegovy to patients in certain professions for $99 a month , Reuters says. Compounded GLP-1 injections are fulfilled and shipped from Hims & Hers affiliated pharmacies and are regulated by the FDA.

Compounding 105

Compounding Compounding Pharmacies Packaging Insurance 105

Pharmaceutical Technology

MAY 12, 2023

GlobalData analyst consensus forecasts project sales to reach $11.5bn by 2029, a 29% compound annual growth rate (CAGR). GlobalData analysts predict the total revenue to be generated from currently marketed Seagen ADCs to be roughly $30bn through 2029. targeting ADC.

Chemotherapy 64

Chemotherapy Compounding 64

Pharmaceutical Technology

APRIL 28, 2023

In 2022, US sales of Ozempic contributed to 65% of global sales; this is expected to continue, with the US market forecast to continue capturing the majority of sales, generating $71bn between 2023–2029. It is forecast that Ozempic will sustain its sales growth over the next five years, with an expected annual sales figure of $17bn in 2029.

Compounding 52

Compounding Dosage Labelling FDA 52

PharmaShots

FEBRUARY 22, 2023

In the US, Trulicity is protected by a compound patent (2027) and by biologics data protection (2026). Hence, it needs to protect its patent as Trulicity patents are very vital to the company’s business as a whole.

Insurance 64

Insurance Compounding Dosage Communication 64

European Pharmaceutical Review

JANUARY 18, 2024

Insomnia market Dual orexin receptor antagonists (DORAs) [dual orexin receptor antagonists (DORAs)]… offer a new mechanism of action [in treating insomnia]” Across the seven major markets, the insomnia market is anticipated to grow at a compound annual growth rate (CAGR) of 2.6 percent from $3.2 billion in 2022 to $4.1

Compounding 98

Compounding 98

pharmaphorum

DECEMBER 20, 2022

He said ensifentrine will “change the treatment paradigm” for COPD by providing bronchodilation and anti-inflammatory properties in one compound. Shares in Verona popped on the news, rising more than 40% to approach $19.50 and drive the company’s market cap to almost $1.5

Compounding 59

Compounding 59